AVEO Oncology announces positive CHMP opinion for tivozanib as treatment of advanced RCC
AVEO Oncology announced the CHMP of the EMA has recommended FOTIVDA™ (tivozanib) for approval as treatment for patients with advanced renal cell carcinoma. If approved by the EC, marketing authorization for tivozanib will be granted in all 28 countries of the EU, Norway, Iceland and Liechtenstein. June 23, 2017